Price T Rowe Associates Inc. MD Buys 3,238 Shares of Enfusion, Inc. (NYSE:ENFN)

Price T Rowe Associates Inc. MD raised its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 19.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 19,746 shares of the company’s stock after purchasing an additional 3,238 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Enfusion were worth $204,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in shares of Enfusion during the 4th quarter worth about $75,000. Dark Forest Capital Management LP acquired a new stake in shares of Enfusion during the 4th quarter valued at about $128,000. Tower Research Capital LLC TRC boosted its position in shares of Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock valued at $136,000 after acquiring an additional 4,889 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Enfusion during the 4th quarter valued at about $144,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Enfusion during the 4th quarter valued at about $191,000. Institutional investors own 81.05% of the company’s stock.

Insider Buying and Selling at Enfusion

In other news, COO Neal Pawar sold 2,769 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $31,788.12. Following the transaction, the chief operating officer now directly owns 1,231,627 shares in the company, valued at approximately $14,139,077.96. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Oleg Movchan sold 11,452 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.39, for a total transaction of $130,438.28. Following the transaction, the chief executive officer now owns 631,847 shares in the company, valued at $7,196,737.33. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,223 shares of company stock worth $754,778 over the last ninety days. Corporate insiders own 36.44% of the company’s stock.

Enfusion Stock Performance

Shares of Enfusion stock opened at $10.85 on Friday. The firm’s 50-day simple moving average is $10.91 and its 200-day simple moving average is $10.67. Enfusion, Inc. has a twelve month low of $7.83 and a twelve month high of $11.80. The firm has a market cap of $1.40 billion, a P/E ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, equities analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.